[Treatment of hypertensive patients with impaired glucose tolerance (IGT)].
Yoshida
Daisuke
D
Second Department of Internal Medicine, Sapporo Medical University School of Medicine.
Higashiura
Katsuhiro
K
Shimamoto
Kazuaki
K
D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000145:classification / Q000627:therapeutic use*; D001161:Arteriosclerosis / Q000209:etiology / Q000517:prevention & control; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D002216:Captopril / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000209:etiology; D002986:Clinical Trials as Topic; D003920:Diabetes Mellitus / Q000209:etiology / Q000517:prevention & control; D018149:Glucose Intolerance / Q000150:complications* / Q000503:physiopathology; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000209:etiology*; D007333:Insulin Resistance; D008019:Life Style; D019808:Losartan / Q000627:therapeutic use; D009543:Nifedipine / Q000627:therapeutic use; D012306:Risk
D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D002216:Captopril; D009543:Nifedipine; D019808:Losartan